Immunogenicity and safety of a hexavalent meningococcal outer-membrane- vesicle vaccine in children of 2-3 and 7-8 years of age

Vaccine

Volumn 18, Issue 15, 2000, Pages 1456-1466

  De Kleijn, Ester D ^a   De Groot, Ronald ^a   Labadie, Jerry ^b   Lafeber, Arianne B ^b   Van Den Dobbelsteen, Germie ^b   Van Alphen, Loek ^b   Van Dijken, Harry ^b   Kuipers, Betsy ^b   Van Omme, Gijs Willem ^c   Wala, Mayke ^d   Juttmann, Ricardo ^d   Rümke, Hans C ^b  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c Public Health Service of the Rotterdam Region   (Netherlands)

^d Home Care Organisation   (Netherlands)

Author keywords

Bactericidal activity; Neisseria meningitidis; Outer membrane vesicle vaccines

Indexed keywords

BACTERIUM ANTIBODY; HEPATITIS B VACCINE; MENINGOCOCCUS VACCINE; OUTER MEMBRANE PROTEIN;

ANTIBODY TITER; BACTERICIDAL ACTIVITY; CHILD; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B; HUMAN; IMMUNIZATION; IMMUNOGENICITY; MALE; MENINGOCOCCOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANTIBODIES, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; NEISSERIA MENINGITIDIS;

EID: 0033971102     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00423-5     Document Type: Conference Paper

References (50)

1. van der Ende A, Spanjaard L, Dankert J. Bacterial meningitis in the Netherlands. Annual report 1996. Amsterdam: University of Amsterdam: Reference Laboratory for Bacterial Meningitis (AMC, RIVM), 1996.
2. Frasch C.E., Mocca L.F., Karpas A.B. Appearance of new strains associated with group B meningococcal disease and their use for rapid vaccine development. Antonie Van Leeuwenhoek. 53:1987;395-402.
3. Wyle F.A., Artenstein M.S., Brandt B.L., Traumont E.C., Kasper D.L., Alteri P.L., Berman S.L., Lowenthal J.P. Immunologic response of man to group B meningococcal polysaccharide vaccine. J. Infect. Dis. 126:1972;514-522.
4. Azmi F.H., Lucas A.H., Spiegelberg H.L., Granoff D.M. Human immunoglobin M paraproteins cross-reactive with Neisseria meningitidis group B polysaccharide and fetal brain. Infect. Immun. 63:1995;1906-1913.
5. Finne K., Leinonen M., Makela P. Antigenic similarities between brain components and bacteria causing meningitis. Lancet. 2:1983;355-357.
6. Costantino P., Viti S., Podda A., Velmonte M.A., Nencioni L., Rappuoli R. Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine. 10:1992;691-698.
7. Devi S.J., Robbins J.B., Schneerson R. Antibodies to poly[(2-8)-alpha-N-acetylneuraminic acid] and poly[(2-9)-alpha-N-acetylneuraminic acid] are elicited by immunization of mice with Escherichia coli K92 conjugates: potential vaccines for groups B and C meningococci and E. coli K1. Proc. Natl. Acad. Sci. USA. 88:1991;7175-7179.
8. Bartoloni A., Norelli F., Ceccarini C., Rappuoli R., Costantino P. Immunogenicity of meningococcal B polysaccharide conjugated to tetanus toxoid or CRM197 via adipic acid dihydrazide. Vaccine. 1:1995;463-470.
9. Jennings H.J., Roy R., Gamian A. Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine. J. Immunol. 137:1986;1708-1713.
10. Fusco P.C., Farley E.K., Bruge J., Danve B., Gibelin N., Blake M.S., Michon F., Schulz D. Comparison of group B meningococcal conjugate vaccines in adult and infant monkeys: rPorB versus tetanus toxoid as protein carrier. Eleventh international pathogenic Neisseria conference. 1998;: EDK, Nice, France.
11. Mandrell R.E., Zollinger W.D. Human immune response to meningococcal outer-membrane protein epitopes after natural infection or vaccination. Infect. Immun. 57:1989;1590-1598.
12. Guttormsen H.K., Wetzler L.M., Naess A. Humoral immune response to the class 3 outer-membrane protein during the course of meningococcal disease. Infect. Immun. 61:1993;4734-4742.
13. Guttormsen H.K., Wetzler L.M., Solberg C.O. Humoral immune response to class 1 outer-membrane protein during the course of meningococcal disease. Infect. Immun. 62:1994;1437-1443.
14. Orren A., Warren R.E., Potter P.C., Jones A.M., Lachmann P.J., Poolman J.T. Antibodies to meningococcal class 1 outer-membrane proteins in South African complement-deficient and complement-sufficient subjects. Infect. Immun. 60:1992;4510-4516.
15. Poolman J.T., Hopman C.T.P., Zanen H.C. Immunogenicity of meningococcal antigens as detected in patient sera. Infect. Immun. 40:1983;398-406.
16. Rosenqvist E., Hoiby E.A., Wedege E., Kusecek B., Achtman M. The 5C protein of Neisseria meningitidis is highly immunogenic in humans and induces bactericidal antibodies. J. Infect. Dis. 167:1993;1065-1073.
17. Achtman M., Neibert M., Crowe B., Strittmatter W., Kusecek B., Weyse E., Walsh M.J., Slawig B., Morelli G., Moll A., Blake M. Purification of eight class 5 outer-membrane protein variants from a clone of Neisseria meningitidis serogroup A. J. Exp. Med. 168:1988;507-525.
18. Zollinger W.D., Mandrell R.E., Altieri P., Berman S., Lowenthal J., Artenstein M.S. Safety and immunogenicity of a Neisseria meningitidis type 2 protein vaccine in animals and humans. J. Infect. Dis. 137:1978;728-739.
19. Frasch C., Peppler M. Protection against group B Neisseria meningitidis disease: preparation of soluble protein and protein-polysaccharide immunogens. Infect. Immun. 37:1982;271-280.
20. Rosenqvist E., Hoiby E.A., Wedege E., Bryn K., Kolberg J., Klem A., Ronnild E., Bjune G., Nokleby H. Human antibody responses to meningococcal outer-membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect. Immun. 63:1995;4642-4652.
21. Peeters C.C.A.M., Rümke H.C., Meulenbelt J., Schuller M., Kuipers A.J., vd Ley P., Poolman J.T. Phase I clinical trial with a hexavalent PorA containing meningococcal outer-membrane vesicle vaccine. Vaccine. 14:1996;1009-1015.
22. Frasch C., Coetzee G., Zahradnik J., Feldman H., Koornhof H. Development and evaluation of serogroup B serotype 2 protein vaccines: report of a serogroup B field trial. Med. Trop. 43:1983;177-183.
23. Sierra V., Campa C., Garcia L., et al. Effecacy evaluation of the Cuban vaccine VA-MENGOC-BC against disease caused by serogroup B Neisseria meningitidis. Achtman M., et al. Neisseria 1990. 1991;129-134 Walter de Gruyter, Berlin.
24. De Moraes J., Perkins B., Camargo M., Hidalgo N., Barbosa H., Sacchi C., et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet. 340:1992;1074-1078.
25. Bjune G., Hoiby E.A., Gronnesby J.K., Arnesen O., Fredriksen J.H., Halstensen A., Holten E., Lindbak A.K., Nokleby H., Rosenqvist E., et al. Effect of outer-membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet. 338:1991;1093-1096.
26. Zollinger W., Boslego J., Moran E., Garcia J., Cruz C., Ruiz S., et al. Meningococcal serogroup B vaccine protection trial and follow-up studies. NIPH Ann. 14:1991;211-213.
27. Goldschneider I., Gotschlich E.C., Artenstein M.S. Human immunity to the meningococcus. II. Development of natural immunity. J. Exp. Med. 129:1969;1327-1348.
28. Goldschneider I., Gotschlich E.C., Artenstein M.S. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med. 129:1969;1307-1326.
29. Goldschneider I., Lepow M.L., Gotschlich E.C., Mauck F.T., Bachl F., Randolph M. Immunogenicity of group A and group C meningococcal polysaccharides in human infants. J. Infect. Dis. 128:1973;769-776.
30. Wedege E., Froholm L.O. Human antibody to a group B serotype 2a meningococcal vaccine determined by immunoblotting. Infect. Immun. 51:1986;571-578.
31. Milagres L.G., Ramos S.R., Sacchi C.T., Melles C.E., Vieira V.S., Sato H., Brito G.S., Moraes J.C., Frasch C.E. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer-membrane protein vaccine: comparison with efficacy. Infect. Immun. 62:1994;4419-4424.
32. Naess L.M., Oftung F., Aase A., Wetzler L.M., Sandin R., Michaelsen T.E. Human T cell responses after vaccination with the Norwegian group B meningococcal outer-membrane vesicle vaccine. Infect. Immun. 66:1998;959-965.
33. Zollinger W.D., Moran E. Meningococcal vaccines: present and future. Trans. R. Soc. Trop. Med. Hyg. 85:1991;37-43.
34. Poolman J.T., van der Ley P.A., Wiertz E.J., Hoogerhout P. Second generation meningococcal OMP-LPS vaccines. NIPH Ann. 14:1991;233-241.
35. Perkins B.A., Jonsdottir K., Briem H., Griffiths E., Plikaytis B.D., Hoiby E.A., Rosenqvist E., Holst J., Nokleby H., Sotolongo F., Sierra G., Campa H.C., Carlone G.M., Williams D., Dykes J., Kapczynski D., Tikhomirov E., Wenger J.D., Broome C.V. Immunogenicity of two efficacious outer-membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J. Infect. Dis. 177:1998;683-691.
36. Van der Ley P., Poolman J.T. Construction of a multivalent meningococcal vaccine strain based on the class 1 outer-membrane protein. Infect. Immun. 60:1992;3156-3161.
37. van der Ley P., van der Biezen J., Poolman J.T. Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer-membrane vesicle vaccine. Vaccine. 13:1995;401-407.
38. Cartwright K., Morris R., Rümke H., Fox A., Borrow R., Begg N., Richmond P., Poolman J. Immunogenicity and reactogenicity in UK infants of a novel vesicle vaccine containing multiple class 1 (PorA) outer-membrane proteins. Vaccine. 17:1999;2612-2619.
39. Claassen I., Meylis J., vd Ley P., Peeters C., Brons H., Robert J., Borsboom D., vd Ark A., v Straaten I., Roholl P., Kuipers B., Poolman J. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer-membrane protein containing vesicle vaccine. Vaccine. 14:1996;1001-1008.
40. Rouppe van der Voort E.M., van der Ley P., van der Biezen J., George S., Tunnela O., van Dijken H., Kuiers B., Poolman J.T. Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent outer-membrane vesicle vaccine. Infect. Immun. 64:1996;2745-2751.
41. Tappero J.W., Lagos R., Ballesteros A.M., Plikaytis B., williams D., Dykes J., Gheesling L.L., Carlone G.M., Hoiby E.A., Holst J., Nokleby H., Rosenqvist E., Sierra G., Campa C., Sotolongo F., Vega J., Garcia J., Herrera P., Poolman J.T., Perkins B.A. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. Jama. 281:1999;1520-1527. [see comments].
42. Boslego J., Garcia J., Cruz C., Zollinger W., Brandt B., Ruiz S., Martinez M., Arthur J., Underwood P., Silva W., et al. Efficacy, safety and immunogenicity of a meningococcal group B (15:P1.3) outer-membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine. 13:1995;821-829.
43. Rosenqvist E, Hoiby EA, Bjune G, Bryn K, Closs O, Feiring B, Klem A, Nokleby H, Frolm LO. Human antibody responses after vaccination with the Norwegian group B meningococcal outer-membrane vesicle vaccine: results from ELISA studies. NIPH Ann. 1991;14:169-79: Discussion 180-1.
44. Hoiby EA, Rosenqvist E, Froholm LO, Bjune G, Feiring B, Nokleby H, Ronnild E. Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer-membrane vesicle vaccine: a brief survey. NIPH Ann. 1991;14:147-55; Discussion 155-6.
45. Wedege E., Michaelsen T.E. Human immunoglobulin G subclass immune response to outer-membrane antigens in meningococcal group B vaccine. J. Clin. Microbiol. 25:1987;1349-1353.
46. Sjursen H., Wedege E., Rosenqvist E., Naess A., Halstensen A., Matre R., Solberg C.O. IgG subclass antibodies to serogroup B meningococcal outer-membrane antigens following infection and vaccination. Apmis. 98:1990;1061-1069.
47. Naess L.M., Rosenqvist E., Hoiby E.A., Michaelsen T.E. Quantitation of IgG subclass antibody responses after immunization with a group B meningococcal outer-membrane vesicle vaccine, using monoclonal mouse-human chimeric antibodies as standards. J. Immunol. Methods. 196:1996;41-49.
48. van den Dobbelsteen G., Kuipers B., van Dijken H., Labadie J., Rümke H., van Alphen L. Isotype distribution of antibodies induced in toddlers and schoolchildren after immunization with RIVM hexavalent PorA vesicle vaccine. Eleventh International Pathogenic Neisseria Conference. 1998;EDK, Nice, France.
49. van den Dobbelsteen G., van Dijken H., Kuipers B., Rümke H., van Alphen L. RIVM hexavalent PorA vesicle vaccine induced antibodies are bactericidal to wild type isolates. Eleventh international pathogenic Neisseria conference. 1998;EDK, Nice, France.
50. Gotschlich E.C., Goldschneider I., Artenstein M.S. Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J. Exp. Med. 129:1969;1367-1384.